BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 32980890)

  • 1. Association of three factors (ABCB1 gene expression, steroid response, early response at day + 8) on the response to induction in patients with acute lymphoblastic leukemia.
    Ramos-Peñafiel C; Olarte-Carrillo I; Maldonado RC; de la Cruz Rosas A; Collazo-Jaloma J; Martínez-Tovar A
    Ann Hematol; 2020 Nov; 99(11):2629-2637. PubMed ID: 32980890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
    Tzortzatou-Stathopoulou F; Papadopoulou AL; Moschovi M; Botsonis A; Tsangaris GT
    J Pediatr Hematol Oncol; 2001 Dec; 23(9):591-7. PubMed ID: 11902303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of metformin on the survival of patients with ALL who express high levels of the ABCB1 drug resistance gene.
    Ramos-Peñafiel C; Olarte-Carrillo I; Cerón-Maldonado R; Rozen-Fuller E; Kassack-Ipiña JJ; Meléndez-Mier G; Collazo-Jaloma J; Martínez-Tovar A
    J Transl Med; 2018 Sep; 16(1):245. PubMed ID: 30176891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of the ABCB1 and ABCG2 gene expression levels in acute lymphoblastic leukemia.
    Olarte Carrillo I; Ramos Peñafiel C; Miranda Peralta E; Rozen Fuller E; Kassack Ipiña JJ; Centeno Cruz F; Garrido Guerrero E; Collazo Jaloma J; Nacho Vargas K; Martínez Tovar A
    Hematology; 2017 Jun; 22(5):286-291. PubMed ID: 27960630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wilms' tumour gene (wt1) expression at diagnosis has no prognostic relevance in childhood acute lymphoblastic leukaemia treated by an intensive chemotherapy protocol.
    Gaiger A; Linnerth B; Mann G; Schmid D; Heinze G; Tisljar K; Haas OA; Gadner H; Lion T
    Eur J Haematol; 1999 Aug; 63(2):86-93. PubMed ID: 10480287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of early anthracycline dose-intensity according to expression of Philadelphia chromosome/BCR-ABL rearrangements in B-precursor adult acute lymphoblastic leukemia.
    Bassan R; Rohatiner AZ; Lerede T; Di Bona E; Rambaldi A; Pogliani E; Rossi G; Fabris P; Morandi S; Casula P; Carter M; Lambertenghi-Deliliers G; Lister TA; Barbui T
    Hematol J; 2000; 1(4):226-34. PubMed ID: 11920195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low expressions of ARS2 and CASP8AP2 predict relapse and poor prognosis in pediatric acute lymphoblastic leukemia patients treated on China CCLG-ALL 2008 protocol.
    Cui L; Gao C; Zhang RD; Jiao Y; Li WJ; Zhao XX; Liu SG; Yue ZX; Zheng HY; Deng GR; Wu MY; Li ZG; Jia HT
    Leuk Res; 2015 Feb; 39(2):115-23. PubMed ID: 25530566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial of induction therapy (daunorubicin, vincristine, prednisone versus daunorubicin, vincristine, prednisone, cytarabine and 6-thioguanine) in adult acute lymphoblastic leukemia with long-term follow-up: an Eastern Cooperative Oncology Group Study (E3486).
    Wiernik PH; Cassileth PA; Leong T; Hoagland HC; Bennett JM; Paietta E; Oken MM;
    Leuk Lymphoma; 2003 Sep; 44(9):1515-21. PubMed ID: 14565653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of the efficacy of two successive protocols on pediatric acute lymphoblastic leukemia with E2A-PBX1 fusion gene].
    Mei YY; Gao C; Cui L; Zhao XX; Zhao W; Li WJ; Wang KL; Jiang J; Zhang RD; Xie J; Shi HW; Wang B; Zhang YH; Ma XL; Zhou X; Wu MY; Li ZG
    Zhonghua Er Ke Za Zhi; 2013 Jun; 51(6):467-71. PubMed ID: 24120066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Escalated daunorubicin dosing as an induction treatment for Philadelphia-negative adult acute lymphoblastic leukemia.
    Lee SM; Lee WS; Shin HJ; Lee JJ; Sohn SK; Moon JH; Eom HS; Won JH; Lee KH; Lee JH; Kim DY; Yoon SS; Kim I; Jung CW; Kim SJ; Kim H; Lee JH; Ryoo HM; Lee GW; Kim SH; Mun YC; Kim MK; Joo YD;
    Ann Hematol; 2013 Aug; 92(8):1101-10. PubMed ID: 23558905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High VLA-4 expression is associated with adverse outcome and distinct gene expression changes in childhood B-cell precursor acute lymphoblastic leukemia at first relapse.
    Shalapour S; Hof J; Kirschner-Schwabe R; Bastian L; Eckert C; Prada J; Henze G; von Stackelberg A; Seeger K
    Haematologica; 2011 Nov; 96(11):1627-35. PubMed ID: 21828124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein expression of the glucocorticoid receptor in childhood acute lymphoblastic leukemia.
    Lauten M; Cario G; Asgedom G; Welte K; Schrappe M
    Haematologica; 2003 Nov; 88(11):1253-8. PubMed ID: 14607754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of high-risk acute lymphoblastic leukemia in children using the AL851 and ALHR88 protocols: a report from the Kyushu-Yamaguchi Children's Cancer Study Group in Japan.
    Matsuzaki A; Ishii E; Okamura J; Eguchi H; Yoshida N; Yanai F; Inoue T; Miyake K; Ishihara T; Tsuboi C
    Med Pediatr Oncol; 1996 Jan; 26(1):10-9. PubMed ID: 7494507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
    Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous detection of MDR1 and WT1 gene expression to predict the prognosis of adult acute lymphoblastic leukemia.
    Xu B; Song X; Yip NC; Xiao P; Zhang Y; Wang W; Zhou S
    Hematology; 2010 Apr; 15(2):74-80. PubMed ID: 20423567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dose related effect of steroids on blast reduction rate and event free survival in children with acute lymphoblastic leukemia.
    Yetgin S; Cetin M
    Leuk Lymphoma; 2003 Mar; 44(3):489-95. PubMed ID: 12688320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Long-term destiny of adolescents and young adults with de novo acute lymphoblastic leukemia treated with a pediatric protocol type].
    López-Hernández MA; Alvarado-Ibarra M; Álvarez-Veral JL; Ortiz-Zepeda M; Guajardo-Leal ML; Cota-Range X
    Gac Med Mex; 2016; 152(5):439-443. PubMed ID: 27792701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia.
    Piatopoulou D; Avgeris M; Drakaki I; Marmarinos A; Xagorari M; Baka M; Pourtsidis A; Kossiva L; Gourgiotis D; Scorilas A
    Ann Hematol; 2018 Jul; 97(7):1169-1182. PubMed ID: 29556721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol.
    Steinherz PG; Redner A; Steinherz L; Meyers P; Tan C; Heller G
    Cancer; 1993 Nov; 72(10):3120-30. PubMed ID: 8221579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone.
    Weiss M; Maslak P; Feldman E; Berman E; Bertino J; Gee T; Megherian L; Seiter K; Scheinberg D; Golde D
    J Clin Oncol; 1996 Sep; 14(9):2480-5. PubMed ID: 8823326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.